Houston Pharmaceuticals, Inc.

Houston, TX

UEI
L43AJUGH1GD3
CAGE
47WV4
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
NAICS codes registered in SAM.gov
SAM.gov registration date
Physical address
4239 Emory Ave, Houston, TX 77005, USA

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Recent federal awards

Houston Pharmaceuticals, Inc.'s 5 most recent federal contract and grant awards, newest first. Amounts are dollars obligated.
Award Agency Obligated Awarded
Targeted radionuclide therapy of pancreatic cancer Contract · HHSN261201600018C National Cancer Institute $298,934
Highly innovated targeted therapy of melanoma Grant · R43CA210839 National Cancer Institute $211,093
Inhibition of stat-3 to stimulate immune function for GBM Grant · R43AI077225 National Institutes of Health $146,989
Preclinical development of WP1066 an effective inhibitor of STAT3 activation for Grant · R44AI077225 National Institutes of Health $840,603
Thermally targeted delivery of DOX Grant · R43CA126318 National Institutes of Health $179,980

Quick answers

What is Houston Pharmaceuticals, Inc.'s UEI?

Houston Pharmaceuticals, Inc.'s Unique Entity ID (UEI) in SAM.gov is L43AJUGH1GD3.

What is Houston Pharmaceuticals, Inc.'s CAGE code?

Houston Pharmaceuticals, Inc.'s CAGE code is 47WV4.

What is Houston Pharmaceuticals, Inc.'s primary NAICS code?

Houston Pharmaceuticals, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).

Where is Houston Pharmaceuticals, Inc. located?

Houston Pharmaceuticals, Inc.'s physical address in SAM.gov is 4239 Emory Ave, Houston, TX 77005, USA.

Is Houston Pharmaceuticals, Inc. registered in SAM.gov?

Yes. Houston Pharmaceuticals, Inc.'s SAM.gov registration is active through May 3, 2027.

What is Houston Pharmaceuticals, Inc.'s most recent federal award?

Houston Pharmaceuticals, Inc.'s most recent federal contract award is Targeted radionuclide therapy of pancreatic cancer (HHSN261201600018C), from National Cancer Institute, on September 19, 2016.

On GovTribe

See Houston Pharmaceuticals, Inc.'s full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login